Novillo Matías, Albergo José I, Huespe Iván, Latallade Valentino, Farfalli Germán L, Ayerza Miguel Ángel, Roitman Pablo, Cayol Federico, Aponte-Tinao Luis A
Servicio de Ortopedia y Traumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. E-mail:
Sector de Ortopedia Oncológica y Trasplantes Óseos, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Medicina (B Aires). 2023;83(5):737-743.
Synovial sarcoma is an unusual tumor with an incidence of 1-3 cases per million. It is more frequent in teenagers and young adults under 30. It develops anywhere, but the extremities are the most frequent place of appearance (80% extremities, 20% other locations: 8% trunk, 7% retroperitoneal/abdominal, 5% head and neck). Oncological results are different depending on the study. Survival rate free of local recurrence, survival rate free of events and global survival rate vary upon published studies. The same happens with the disease's prognostic factors.
The objective was to analyze a group of 43 patients with diagnosis of synovial sarcoma of the extremities treated surgically and determine (1) global survival rate, (2) survival rate free of events, (3) local recurrence rate and (4) oncological risk factors.
The global survival rate at 2 years was 90% (IC95%: 76 - 96%) and 67% (IC95%: 49-80%) at 5 years. The survival rate free of events at 2 years was 68% (IC95% 51-80%) and 48% (IC95% 32-52%) at 5 years. The recurrence rate at 2 years was 9% (IC95% 3-25%) and 25% (IC95% 13-46%) at 5 years. The histological grade and metastatic presence were bad prognostic factors.
We can conclude that our oncological results are in line with those published in previous series and that there were two factors associated with poor prognosis.
